sage of a single dose of Tranexamic acid for reduction of blood loss in patients undergoing unilateral primary total knee replacement surgery
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2023/10/058283
- Lead Sponsor
- Sriman Narayan M
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
1. Patients undergoing Unilateral Total Knee Replacement.
2. Both sexes.
3. Patients with Hemoglobin levels equal to more than 11g/dL.
4. Coagulation profile within normal limits.
1. Patients undergoing simultaneous bilateral Total Knee Replacement Surgery.
2. Patient undergoing revision Knee Replacement surgeries.
3. Known patients of bleeding disorders.
4. Patients with known cases of Deep Vein Thrombosis, Pulmonary Embolism, and other vessel wall disorders.
5. Known cases of hematological disorders.
6. Known cases of renal insufficiency.
7. Patients with a Wells Score 2 or more.
8. Patients with a previous history of Cerebrovascular accidents, Transient Ischemic Attack, or Myocardial infarction.
9. Patient with a known history of seizure disorder.
10.Patients with known or suspected allergy to medication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood loss, measured by drain output, drop in Hemoglobin, and Packed Cell Volume. Intraoperatively, by the number of swabs and gauze soaked, field loss, and irrigation aspirator volume.Timepoint: Blood loss, measured by drain output at 24 hours and 48 hours postoperatively, drop in Hemoglobin and Packed Cell Volume on postoperative day 1 and postoperative day 5.
- Secondary Outcome Measures
Name Time Method Requirement of blood transfusionTimepoint: Intraoperatively during the time of surgery, on postoperative day 1, on postoperative day 5.